← All trials
NCT04145258
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2020
- Primary completion
- Jul 30, 2023
- Completion date
- Dec 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 768
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of FranceLead sponsor
- University of BordeauxOverall official - principal investigator
- European UnionCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.